<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03897270</url>
  </required_header>
  <id_info>
    <org_study_id>I 60217</org_study_id>
    <secondary_id>NCI-2019-01356</secondary_id>
    <secondary_id>I 60217</secondary_id>
    <nct_id>NCT03897270</nct_id>
  </id_info>
  <brief_title>Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects</brief_title>
  <official_title>Photoacoustic Imaging of Human Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Susan G. Komen Breast Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies photoacoustic imaging of the breast in patients with breast cancer and&#xD;
      healthy subjects. Dense breasts typically reduce the sensitivity of a mammography and also is&#xD;
      associated with a higher risk of breast cancer. Photoacoustic tomography combines light and&#xD;
      sound to provide more information about breast tissue.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To identify photoacoustic features of breast malignancy.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Participants undergo photoacoustic imaging of the breast over 30 minutes. At subject's&#xD;
      discretion, imaging may repeat for a total of 10 studies, each in a separate day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Translating system to 2nd generation&#xD;
  </why_stopped>
  <start_date type="Actual">October 18, 2018</start_date>
  <completion_date type="Anticipated">October 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 18, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identify photoacoustic features of breast malignancies</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Photoacoustic excitation and detection will be performed</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Breast Carcinoma</condition>
  <condition>Healthy Subject</condition>
  <arm_group>
    <arm_group_label>Diagnostic (photoacoustic imaging of the breast)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo photoacoustic imaging of the breast over 30 minutes. At subject's discretion, imaging may repeat for a total of 10 studies, each in a separate day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Photoacoustic Imaging</intervention_name>
    <description>Undergo photoacoustic imaging of the breast</description>
    <arm_group_label>Diagnostic (photoacoustic imaging of the breast)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with clinically suspicious or confirmed breast cancer masses (that have not been&#xD;
             surgically removed) and will/have already undergo/undergone breast magnetic resonance&#xD;
             imaging (MRI).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women (there are no known risks to these procedures, but any unforeseen risks&#xD;
             are as yet undetermined, so pregnant women will be excluded by means of a verbal&#xD;
             confirmation at time of screening).&#xD;
&#xD;
          -  Women who have had breast implants in the previous 6 months.&#xD;
&#xD;
          -  Women who have had lumpectomy or are undergoing neoadjuvant chemotherapy.&#xD;
&#xD;
          -  Adults unable to consent.&#xD;
&#xD;
          -  Individuals who are not yet adults (infants, children, teenagers).&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Prisoners.&#xD;
&#xD;
          -  There is no direct benefit of the study to any subject either non-English or English&#xD;
             speaker. To facilitate the consent process, we will exclude non-English speaking&#xD;
             subjects.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ermelinda Bonaccio</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 22, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

